GET DAILY SIGNALSSonoma Pharmaceuticals (SNOA) Reports Record Revenue and First Positive EBITDA
Key Takeaways
- Sonoma Pharmaceuticals reported record quarterly revenue of $6.4 million, up 60% year over year and above the roughly $4.99 million consensus estimate.
- Net loss narrowed sharply to $0.3 million, or $0.09 per share, compared with a $1.2 million loss, or $0.76 per share, in the prior-year quarter.
- The company achieved its first-ever positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a key profitability milestone.
- Gross margin expanded to 40% from 36% a year earlier, while operating expenses remained essentially flat.
- U.S. revenue surged 141% year over year, driven by over-the-counter product sales and new distributor growth.
- For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated ticker pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.
Earnings Context and Why It Matters
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products used in wound care, eye care, dermatology, podiatry, animal health, and non-toxic disinfection. For a small-cap company that has historically posted consistent losses, the fiscal first quarter of 2027 represented a meaningful inflection point. Investors have long watched whether Sonoma's commercial strategy could translate revenue growth into a path toward profitability. The combination of record sales, expanding gross margins, flat operating expenses, and the company's first positive adjusted EBITDA signals that operating leverage is beginning to materialize. Because the company remains unprofitable on a GAAP basis and operates with a limited cash balance, this quarterly report carries outsized weight for shareholders evaluating the durability of the turnaround. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For its first fiscal quarter ended June 30, 2026, Sonoma Pharmaceuticals reported total revenue of $6.4 million, a 60% increase from $4.0 million in the same period last year and above the consensus estimate of approximately $4.99 million. U.S. revenue rose 141%, or $1.4 million, while Europe grew 34%.
Gross profit came in at $2.6 million, representing a 40% gross margin compared with 36% a year earlier. Total operating expenses held flat at $2.6 million, demonstrating the operating leverage in the business model. Loss from operations narrowed to just $40,000 from $1.1 million in the prior-year quarter.
The company's net loss for the quarter was $0.3 million, or $0.09 per share (basic and diluted), down 88% from a net loss per share of $0.76 a year ago. Sonoma also recorded an EBITDA gain of about $0.1 million, its first positive adjusted EBITDA, compared with an EBITDA loss of $1.0 million in the prior-year period. As of June 30, 2026, the company held $5.3 million in cash and cash equivalents. From what I see, these numbers point to real progress on the cost side.
Market Reaction and Investor Sentiment
SNOA trades as a micro-cap stock with a market capitalization of only a few million dollars, which makes its share price especially sensitive to news and low trading volume. The stock has remained under significant pressure over the past year, trading near the lower end of its 52-week range. The August 6, 2026 report delivered results that beat consensus on both revenue and the bottom line, and the achievement of positive adjusted EBITDA marked a notable shift in the company's narrative. However, investors have continued to weigh the progress against ongoing concerns, including the company's GAAP losses, a still-modest cash balance, and the dilutive effect of a substantially higher share count. Sentiment heading into the next report will likely hinge on whether Sonoma can sustain its revenue momentum and extend its profitability milestone.
Forward Outlook and Key Factors to Monitor
Following this report, investors will be watching whether Sonoma can build on its first-ever positive adjusted EBITDA and maintain the pace of revenue growth. The company's U.S. expansion, driven by over-the-counter products and new distributors, will be a central area of focus, as will the performance of its European business, which has benefited from favorable exchange rates.
Regulatory progress remains an important catalyst. In June 2026, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn Wound Irrigation Solution, including expanded claims and additional packaging configurations. New distribution agreements in Taiwan, Vietnam, and the United States also support the commercial pipeline.
At the same time, several factors deserve attention. The company's share count increased substantially during the quarter, which dilutes per-share metrics and can pressure the stock. Its cash position of $5.3 million, while improved, still requires disciplined cost management as the company continues to pursue growth. Margin sustainability, order timing in Asia and Latin America, and any potential capital-raising activity will all be key variables to monitor in the quarters ahead. I’m watching this closely for signs of sustained momentum.
Exploring AI Tools for Stock Analysis
In my view, tools like Tickeron’s AI-powered platforms can help investors quickly compare small-cap healthcare names and spot emerging patterns without spending hours on manual research. I find the AI Screener particularly useful for filtering by fundamentals and technical signals when evaluating companies like this one. It has become part of my regular process for identifying comparable setups across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SNOA sees its Stochastic Oscillator ascends from oversold territory
On October 29, 2026, the Stochastic Oscillator for SNOA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 50 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SNOA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNOA as a result. In 88 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SNOA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SNOA moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SNOA crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNOA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SNOA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.799) is normal, around the industry mean (8.029). P/E Ratio (-0.902) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. SNOA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNOA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of prescription and non-prescription products
Industry PharmaceuticalsGeneric
Advertisement